Ricardo Pineiro Hernandez
Payments from drug & device makers
Across 161 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$423
- Novo Nordisk$401
- Tandem Diabetes Care, Inc.$349
- Medtronic$248
- Lilly USA, LLC$243
- Corcept Therapeutics$157
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,267100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $423 |
| Novo Nordisk | 29 | $401 |
| Tandem Diabetes Care, Inc. | 9 | $349 |
| Medtronic | 3 | $248 |
| Lilly USA, LLC | 15 | $243 |
| Corcept Therapeutics | 9 | $157 |
| Insulet Corporation | 11 | $150 |
| Boehringer Ingelheim | 6 | $133 |
| Novartis | 6 | $126 |
| Bayer | 6 | $126 |
| GSK | 4 | $92 |
| Madrigal Pharmaceuticals | 3 | $66 |
| Phathom Pharmaceuticals, Inc. | 3 | $63 |
| Xeris Pharmaceuticals, Inc. | 3 | $62 |
| Pfizer | 4 | $60 |
| Ardelyx, Inc. | 3 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Dexcom, Inc. | 3 | $53 |
| Amneal Pharmaceuticals LLC | 2 | $36 |
| Astellas Pharma US Inc | 2 | $35 |
| Exact Sciences | 2 | $35 |
| AbbVie | 2 | $33 |
| Edwards Lifesciences | 1 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Amgen | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Saluda Medical Americas, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,267 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 154 | $151,008 |
| JardianceEmpagliflozin | 108 | $87,867 |
| FarxigaDapagliflozin Propanediol | 78 | $58,157 |
| EliquisApixaban | 54 | $39,400 |
| MounjaroTirzepatide | 27 | $27,831 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $23,741 |
| TrulicityDulaglutide | 16 | $15,257 |
| VascepaIcosapent Ethyl | 30 | $14,884 |
| TradjentaLinagliptin | 20 | $14,738 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $9,088 |
| LivaloPitavastatin Calcium | 18 | $7,246 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $3,357 |
| SynthroidLevothyroxine Sodium | 32 | $2,549 |
| LantusInsulin Glargine,hum.Rec.Anlog | 27 | $1,973 |
| LevemirInsulin Detemir | 17 | $1,855 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Levemir, Novolog | $401 | $153,984183 claims |
| Boehringer IngelheimJardiance, Tradjenta | $133 | $102,605128 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $423 | $67,24590 claims |
| Lilly USA, LLCMounjaro, Trulicity | $243 | $43,08843 claims |
| PfizerEliquis | $60 | $39,40054 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $31 | $7,24618 claims |
| AbbVieSynthroid | $33 | $2,54932 claims |
| Sanofi-aventis U.S. LLCLantus | $21 | $1,97327 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $36 | $988173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Miami
- Stephanie MompointMiami$4.5M
- Itsel Cardenas RamonMiami$1M
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- John HuffakerVenice$8M
- Miguel TrujilloMiami Gardens$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.